Having failed to find a buyer, Aurinia Pharmaceuticals has resorted to slashing its workforce and R&D pipeline to stay afloat.
Key Takeaways
-
Aurinia’s search for a buyer has drawn a blank – forcing it to downsize it staff and R&D pipeline
-
The company’s single marketed product Lupkynis is expected to increase sales this year, which could provide it with stable long-term business
The company is now pinning its hopes on building sales of its sole marketed therapy, the lupus nephritis treatment Lupkynis (voclosporin),
